A Risk-Based Approach for Establishing Genomic Integrity and Stability for Genetically-Engineered, Allogenic Cell Therapy Products

Time: 11:45 am
day: Day Two


• Discuss challenges of evaluating off target integration in genetically engineered products

• Discuss different approaches on off target assessment

• How to evaluate change in variants in cell therapy product throughout the manufacturing process